AstraZeneca invests $2bn in Summit Therapeutics to co-develop cancer drugs
According to The Guardian Business, AstraZeneca is investing $2 billion in Summit Therapeutics to co-develop and test anti-cancer drugs, with plans to collaborate on a series of studies and to broaden the reach of its ADC portfolio alongside next-generation immunotherapies, including PD-1 targeting bispecifics.
Key facts
- 01Deal amount is $2 billion.
- 02AstraZeneca and Summit Therapeutics will co-develop and test cancer drugs.
- 03They will collaborate on a series of studies testing their cancer treatments together.
- 04The strategy includes broadening the reach of AstraZeneca's ADC portfolio and combining with next-generation immunotherapies, including PD-1 targeting bispecifics.
AI-generated from the sources below. Always check the originals.
How each country tells it
So far our sources show coverage from one country. Perspectives appear once we find reports from a second country.
Sources
Summaries are AI-generated from the linked sources and may contain errors; always check the originals. We summarise and link; we never republish articles. Photos come from openly licensed libraries, official publicity material and brand logos, credited to their sources. If you own an image and want it credited differently or removed, email info@coda.news and we will act promptly.